By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Soligenix 

29 Emmons Drive
Suite C-10
Princeton  New Jersey  08540  U.S.A.
Phone: 609-538-8200 Fax: 609-452-6467


SEARCH JOBS








Company News
Soligenix (SNGX) Announces $1.5 Million NIDCR SBIR Grant Award Supporting The Pivotal Phase III Clinical Trial Of SGX942 For The Treatment Of Oral Mucositis In Head And Neck Cancer 9/20/2017 6:50:27 AM
Soligenix (SNGX) Announces $1.5 Million NCI SBIR Grant Award Supporting The Pivotal Phase III Clinical Trial Of SGX301 For The Treatment Of Cutaneous T-Cell Lymphoma 9/18/2017 6:30:44 AM
Soligenix (SNGX) Announces Recent Accomplishments And Second Quarter 2017 Financial Results 8/14/2017 7:32:16 AM
Soligenix (SNGX) Receives $2.5M In Additional NIAID Funding To Advance Development Of Heat Stable Ricin Vaccine 8/14/2017 6:54:40 AM
Soligenix (SNGX) Initiates Pivotal Phase III Clinical Trial Of SGX942 (Dusquetide) For The Treatment Of Oral Mucositis In Head And Neck Cancer Patients 7/27/2017 6:31:33 AM
Soligenix (SNGX) Release: Dusquetide Technology Platform To Be Presented At The 2017 Drug Discovery And Therapy World Congress 7/6/2017 7:32:07 AM
Soligenix (SNGX) Receives Additional NIAID Funding To Advance Development Of Heat Stable Ricin Vaccine 6/21/2017 8:30:40 AM
Soligenix (SNGX) Release: Complete Efficacy And Long-Term Follow-Up Safety Results From SGX942 Phase II Oral Mucositis Clinical Trial To Be Presented At The 2017 Multinational Association For Supportive Care In Cancer Conference 6/19/2017 6:14:50 AM
Soligenix (SNGX) Announces Publication Of Its Phase II Long-term Follow-up Results Of SGX942 For The Treatment Of Oral Mucositis In Head And Neck Cancer Patients 5/18/2017 6:41:46 AM
Soligenix (SNGX) Announces Recent Accomplishments And First Quarter 2017 Financial Results 5/11/2017 9:15:33 AM
12345678910...
//-->